In the year 2014, a focal point of the group’s development and diversification strategy was witnessed with the decision to invest in the business of Healthcare by acquiring a pharmaceutical manufacturing plant, M/s Bymaa Laboratories Pvt Ltd in the state of Pondicherry, India. This company is involved in manufacture and supply of generic medications covering major therapeutic areas, such as Analgesics, Antipyretic, Antispasmodics, Antidiarrheal, Anti-allergic, Anti-diabetic, Diuretics, Antipsychotics, Antibiotics, Corticosteroids, Cardiovascular drugs, Vitamin B complex, Multivitamins and others in a variety of solid oral dosage forms. 

 

Our state-of-the-art WHO GMP certified manufacturing facility has the capacity to produce over 600 million tablets and 500 million capsules per annum on just a single shift basis. Our plant also boasts a sophisticated DM (De-mineralized) water plant, highly advanced 3600 sqft in-house laboratory dedicated for Quality Control including a specialized area for Microbiology.

Apart from working on fresh registrations for export markets and FRND studies on upcoming patent releasing formulations, Bymaa offers its products and services to marketing companies, drug wholesalers, retail drug chains, distributors, and government agencies in all states of India – Tamil Nadu, Karnataka, Andhra Pradesh, Kerala, Telangana, Gujarat and Maharashtra.